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Intratumoral injection of Semliki Forest virus encoding 
interleukin-12 (SFV-IL-12) combines acute expression of 
IL-12 and stressful apoptosis of infected malignant cells. 
Agonist antibodies directed to costimulatory recep-
tor CD137 (4-1BB) strongly amplify pre-existing cellu-
lar immune responses toward weak tumor antigens. In 
this study, we provide evidence for powerful synergistic 
effects of a combined strategy consisting of intratumoral 
injection of SFV-IL-12 and systemic delivery of agonist 
anti-CD137 monoclonal antibodies (mAbs), which was 
substantiated against poorly immunogenic B16 mela-
nomas (B16-OVA and B16.F10) and TC-1 lung carcino-
mas. Effector CD8β
+ T cells were sufficient to mediate 
complete tumor eradications. Accordingly, there was 
an intensely synergistic in vivo enhancement of cyto-
toxic T lymphocytes (CTL)-mediated immunity against 
the tumor antigens OVA and tyrosine-related protein-2 
(TRP-2). This train of phenomena led to long-lasting 
tumor-specific immunity against rechallenge, attained 
transient control of the progression of concomitant 
tumor lesions that were not directly treated with SFV-
IL-12 and caused autoimmune vitiligo. Importantly, 
we found that SFV-IL-12 intratumoral injection induces 
bright expression of CD137 on most tumor-infiltrating 
CD8+ T lymphocytes, thereby providing more abundant 
targets for the action of the agonist antibody. This effi-
cacious combinatorial immunotherapy strategy offers 
feasibility for clinical translation since anti-CD137 mAbs 
are already undergoing clinical trials and development 
of clinical-grade SFV-IL-12 vectors is in progress.
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IntroductIon
Interleukin-12 (IL-12) is a potent immunotherapeutic cytokine 
usually expressed by activated macrophages and dendritic 
cells. IL-12 has shown strong antitumoral activity mediated 
by activation of cytotoxic T lymphocytes (CTL), T-helper cell 
type 1 responses, NK and NKT cells, as well as by inhibition of 
angiogenesis.1,2 Most of these effects are mediated by the induc-
tion of interferon γ (IFNγ).3 Several viral vectors, such as adeno-
virus, retrovirus, or alphavirus, have been used to deliver IL-12 
to animal tumor models, resulting in localized expression of the 
cytokine and antitumor efficacy.4–6 However, in spite of successful 
preclinical studies, phase I clinical trials performed with adeno-
virus or canarypox vectors-expressing IL-12 only showed minor 
therapeutic effect.7,8 These results indicated a need for more 
potent vectors and for the development of combinatorial strat-
egies.9 Alphavirus vectors based on Semliki Forest virus (SFV) 
have shown some advantages over adenoviral vectors in preclini-
cal studies of cancer treatment, such as higher expression lev-
els, broad tropism, and induction of immunogenic apoptosis in 
tumor cells.10,11 This last property can lead to the release of tumor 
antigens that can be uptaken by antigen-presenting cells, favor-
ing an ensuing antitumor immune response.12 The SFV vector is 
based on a viral RNA genome in which the region coding for the 
structural proteins has been replaced by an heterologous gene.13 
SFV vectors-expressing IL-12 have shown to be very efficient in 
inducing therapeutic antitumor responses in tumor models of 
colon adenocarcinoma, sarcoma, and glioma in mice,10,14,15 ortho-
topic hepatocellular carcinoma in rats,11 or spontaneous hepato-
cellular carcinoma in woodchucks.16
In vivo treatment with agonist agents acting on CD137 
(4-1BB) expressed on primed T cells results in enhancement 
of tumor-eradicating cytotoxic T-cell responses.17 These thera-
peutic effects have been observed with conventional monoclo-
nal antibodies (mAbs) and single chain Fv antibodies attached 
to tumor cells.18 Although originally described as an inducible 
molecule on activated T-cells,19 CD137 is not only expressed 
on antigen-activated T-cells but also on other cell types such 
as activated NK cells,20 dendritic cells,21 and endothelial cells 
in tumor vessels.22 Agonist mAbs given as monotherapy to 
tumor-bearing mice rely mainly on CTL antitumor responses, 
although an involvement for NK cells has been reported in a 
number of cases.23 Particularly, therapeutic CD137 stimulation 
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greatly enhanced the NK-mediated ADCC activity of mAbs 
recognizing tumor-associated surface molecules.24 Moreover, 
anti-CD137 mAbs enhanced lymphocyte infiltration into 
tumors as a result of stimulating tumor endothelial cells to 
behave as those in inflamed tissue.22 Agonist mAbs directed to 
human CD137 (BMS663516 and PF-05082566) are undergo-
ing clinical trials for cancer treatment, the results of which are 
eagerly awaited.25
Synergistic treatments that involved adenoviral gene transfer of 
IL-12 and agonist antibodies anti-CD137 or gene transfer of soluble 
forms of the natural CD137 ligand have been previously reported.26 
The synergistic effects were dependent on T cells and NK cells.27,28 
Our hypothesis was to exploit the powerful proimmunogenic effects 
of a suicidal but cytopathic RNA virus encoding IL-12 with systemic 
costimulation of CD8 T cells by agonist anti-CD137 mAb.
results
Intratumoral sFV-Il-12 synergizes with systemic 
cd137 costimulation
Although the SFV-IL-12 vector has shown a curative antitu-
moral efficacy in some murine models,10,14,15 its efficacy has 
been lower in other tumor models, such as B16 melanoma.29 
We tested whether costimulation with an agonist mAb against 
CD137 could augment the antitumor potency of SFV-IL-12 
vector in B16-OVA tumors. To study a potential synergy, we 
first determined the dose of SFV-IL-12 that was able to pro-
vide a suboptimal therapeutic effect in this melanoma model 
(Supplementary Figure S1). Since both 107 and 108 viral par-
ticles (vp) of SFV-IL-12 were able to provide a suboptimal anti-
tumoral effect, mice bearing established B16-OVA tumors were 
treated intratumorally with each of the selected vector doses, or 
with saline, in combination with an agonist mAb against CD137 
given intraperitoneally (Figure 1a). Control animals were 
treated with the same doses of SFV-IL-12 in combination with 
irrelevant rat immunoglobulin G (IgG). Mice treated with the 
CD137 agonist mAb as a single agent experienced tumor rejec-
tion in only 7% of the cases. As expected, SFV-IL-12 admin-
istration in combination with control IgG induced a modest 
response in treated animals, which rejected 12.5% and 25% of 
tumors intralesionally injected with 107 and 108 vp, respectively. 
In contrast, combined administration of both SFV-IL-12 and 
CD137 mAb greatly increased the therapeutic efficacy observed 
in single-agent treatments, inducing 50% and 75% of complete 
tumor remissions (Figure 1a,b) when the vector dose used 
was 107 or 108 vp, respectively. In order to determine the role 
of SFV cytopathic replication (Supplementary Figure S2a) in 
the antitumoral effect, we treated B16-OVA bearing mice with 
a single injection of 108 vp UV-inactivated SFV-LacZ + 15 ng 
of recombinant murine IL-12 in combination with systemic 
CD137 agonist mAb. As shown in Supplementary Figure S2b, 
SFV replication seemed to be necessary to achieve a good anti-
tumoral synergy with CD137 mAb.
The combinatorial strategy was also tested in the murine lung 
TC-1 tumor model.30 This tumor model expresses human papil-
loma virus (HPV) E6 and E7 genes and has been frequently used 
as a surrogate for human tumors transformed by HPV-16. We 
first determined the dose of SFV-IL-12 that was able to provide 
a minimal therapeutic effect in this model and that would permit 
a demonstration of synergy on established TC-1 tumors of more 
than 5 mm of diameter grafted for 21 days31 (Supplementary 
Figure S3). Accordingly, we proceeded to treat TC-1 tumors by 
combining 107 vp of SFV-IL-12 intratumorally, or saline as control, 
with anti-CD137 mAb. Control mice were treated with the same 
dose of SFV-IL-12 in combination with a nonrelevant rat IgG. 
Animals receiving either SFV-IL-12 or anti-CD137 mAb treat-
ment eradicated 37.5% of tumors. In contrast, combined treat-
ment with SFV-IL-12 and anti-CD137 mAb was able to eradicate 
75% of tumors (Figure 1c). All animals that eliminated tumors 
remained tumor-free until the end of the experiment 4 months 
later (Figure 1d).
To determine whether SFV gene transfer of IL-12 was required 
on the same tumor nodule to display synergistic effects with anti-
CD137 mAb, we conducted experiments in which two tumor nod-
ules were generated by B16-OVA subcutaneous inoculation into 
opposite flanks of the same mouse. Once tumors reached 4–5 mm 
of diameter, one of the nodules in each mouse was inoculated with 
107 or 108 vp of SFV-IL-12, or saline as control, leaving the other 
nodule untreated. Mice receiving SFV-IL-12 in combination with 
anti-CD137 mAb were again able to dramatically increase the 
number of complete regressions of SFV-treated nodules in com-
parison with animals treated with either agent by itself (Figure 2a, 
red lines). Although the effect of SFV-IL-12 + anti-CD137 on non-
treated nodules was more modest, it was able to delay their growth 
in comparison to nontreated tumors from animals treated with 
SFV-IL-12 only (P = 0.0001 for 107 vp and P = 0.021 for 108 vp) 
(Figure 2a, green lines). This delay in tumor growth resulted in 
a longer survival of animals treated with the combined therapy 
(Figure 2b). To check whether this effect could be the result of 
SFV vector reaching nontreated nodules we inoculated mice bear-
ing two tumors with 108 vp of SFV-Luc into one nodule. Luciferase 
expression was detected 24 hours later only in the injected nod-
ules, suggesting that the antitumoral effect observed with SFV-IL-
12+antiCD137 in nontreated tumors could be due to induction of 
a systemic immune response rather than dissemination of the viral 
vector to the contralateral tumor (Supplementary Figure S4). 
This was confirmed by the fact that a higher CD3+ infiltrate was 
observed in nontreated tumors in the SFV-IL-12+antiCD137 
group as compared to nontreated tumors in the SFV-IL-12 or 
saline groups (Supplementary Figure S4b).
Cured animals from these experiments were rechallenged 
with B16-OVA and subsequently with B16.F10 cells, with an 
interval of 3 months between rechallenges. All mice that had 
been cured with SFV-IL-12, with or without anti-CD137, resisted 
the B16-OVA rechallenge, in contrast to the sole survivor treated 
with anti-CD137 monotherapy (Figure 3a). However, only mice 
that had been able to eliminate also the untreated concomitant 
tumors were resistant to the challenge with B16.F10, suggesting 
that the memory immune response generated in those animals 
was more potent.
The expression of OVA in B16 tumor cells provides a xenoan-
tigen which raises the antigenicity of the tumor. An experiment 
on established tumors derived from the B16.F10 cell line was car-
ried out to disregard the need for xenoantigen. B16.F10 tumors 
were treated with each single agent (SFV-IL-12 or agonist CD137 
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mAb) or with the combination of both agents. As it can be seen 
in Figure 3b and c the combined treatment was able to eradicate 
2 out of 6 tumors, while each single agent failed to cure any of 
the mice. Additionally, a noticeable retardation of tumor growth 
was observed in all mice treated with the combination therapy 
(Figure 3b).
cd8+ t cells are essential for the antitumor efficacy 
of combined treatment
In order to determine which immune cell types were involved in 
the antitumoral effect mediated by SFV-IL-12 + anti-CD137 mAb 
therapy, we depleted CD4+, CD8+ T-cells, or NK cells in B16-OVA 
tumor-bearing animals before treatment. CD8+ T-cell depletion 
Figure 1 treatment efficacy of sFV-Il-12 + anti-cd137 combination. (a) C57BL/6 female mice were inoculated in the flank with 5 × 105 B16-OVA 
cells on day 0 and then received an intratumoral injection of saline (top panels), 107 viral particles (vp) (middle panels), or 108 vp of SFV-IL-12 (bottom 
panels) on day 7. On days 7, 10, and 14 mice received intraperitoneally 100 µg of rat immunoglobulin G (IgG) (left panels) or anti-CD137 mAb (right 
panels). (c) C57BL/6 female mice were inoculated in the flank with 5 × 105 TC-1 cells on day 0 and then received an intratumoral injection of saline 
(top panels) or 107 vp of SFV-IL-12 (bottom panels) on day 18. On days 18, 22, and 26 mice received intraperitoneally 100 µg of rat immunoglobulin 
G (IgG) (left panels) or anti-CD137 mAb (right panels). (a,c) Each curve represents the evolution of the mean tumor diameter for each individual 
mouse. The numbers in the right lower corner of each graph indicate the fraction of tumor-free mice on day 60 (for the B16-OVA model) or on 
day 121 (for the TC-1 model) relative to the total number of animals in each group, and the percentage of complete tumor regressions, respectively. 
(b,d) Kaplan–Meier plots of mouse survival. The SFV-IL-12 + anti-CD137-treated group (108 vp in b) was compared with the rest of the groups with 
the log-rank test. n.s., not significant; *P < 0.05; ** P < 0.01;*** P < 0.001. (a,b) The graphs correspond to pooled data of two independent experi-
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completely abrogated the antitumoral effect of the combined treat-
ment, while CD4+ T-cell or NK depletion did not (Figure 4a). 
Although CD8+ T-cell depletion with anti-CD8β mAb prevented 
tumor eradications, a moderate delay in tumor growth was still 
observed in these mice, which led to a significantly longer survival 
in comparison to saline-treated animals (Figure 4b). We wondered 
whether the tumor growth delay observed in CD8+ T-cell-depleted 
mice could be due to NK cells. Double depletion of CD8+ T and NK 
cells resulted in a delay in tumor growth similar to that observed 
in CD8+ T-cell-depleted animals, indicating that NK cells were not 
involved in this effect, in contrast to previous observations with 
IL-12 gene therapy + CD137 agonist antibodies.27
combined therapy induces dramatic increases in 
cd8+ t-cell numbers and tumor-specific ctls
To further determine the immune cellular mechanisms that are 
taking place in the tumor environment, we characterized tumor 
infiltrating lymphocytes (TILs). It is broadly accepted that a posi-
tive ratio between effector CD8+ T and Treg cells within the tumor 
is a good sign of prognosis. Indeed, this was the case in all animals 
treated with SFV-IL-12, where a significant increase in the num-
ber of CD8+ T-cells was accompanied by a reduction in the num-
ber of Treg cells (Figure 5a,b) both in terms of percentage and 
absolute numbers. Interestingly, tumor infiltrating CD8+ T-cells 
from animals treated with the combined therapy exhibited a blast 
transformation phenotype, showing higher size and complex-
ity upon fluorescence-activated cell sorting (FACS) examination 
(Figure 5c). The analysis of tumors also showed that mice receiv-
ing anti-CD137 mAb, with or without SFV-IL-12, had reduced 
numbers of tumor-infiltrating CD4+ T-cells (Supplementary 
Figure S5). NK and NKT cells were diminished in tumors of mice 
treated with SFV-IL-12, agonist anti-CD137 mAb, or both. Some 
changes were also observed in the myeloid-derived compart-
ment of the tumor stroma, encompassing an elevation of Ly6G+ 
Ly6Cint or low cells in mice treated with the combination therapy 
(Supplementary Figure S5). However, in spite of these changes 
selective depletions of Ly6G+ and Ly6C+ cells did not alter the 
combined therapeutic efficacy (Supplementary Figure S6).
Mice treated with the combination of SFV-IL-12 and anti-
CD137 mAb exhibited a huge increase in the percentage of cir-
culating CD8+ lymphocytes which reached a maximum of 40% 
at 19 days after tumor treatment (Figure 6a,b). Agonist CD137 
mAb by itself also boosted the percentage of circulating CD8+ 
T cells but in a much less pronounced manner. Importantly, 
CD8+ T-cells specific for OVA peptide SIINFEKL and for 
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Figure 2 treatment efficacy of sFV-Il-12 + anti-cd137 combination on bilateral B16-oVA tumors. (a) C57BL/6 female mice were inoculated in 
contralateral flanks with 5 × 105 B16-OVA cells on day 0 and then received in the right tumor an injection of saline (top panels), 107 viral particles (vp) 
(middle panels), or 108 vp of SFV-IL-12 (bottom panels) on day 8. On days 8, 11, and 15 mice received intraperitoneally 100 µg of rat immunoglobulin 
G (IgG) (left panels) or anti-CD137 mAb (right panels). Red curves represent the evolution of SFV-IL-12-treated tumor diameter and green dotted 
curves represent the evolution of the nontreated tumor diameter for each individual mouse. Red numbers in the right lower corner of each graph 
indicate the number of completely rejected treated-tumors and green numbers indicate the number of completely rejected contralateral tumors on 
day 84 relative to the total number of animals in each group, and the percentage of complete tumor regressions, respectively. (b) Kaplan–Meier plot 
of mouse survival. The SFV-IL-12 (108 vp) + anti-CD137-treated group was compared with the rest of the groups with the log-rank test. n.s., not 
significant; *P < 0.05; **P < 0.01;***P < 0.001. The graphs correspond to pooled data from two independent experiments with similar results. α, anti-; 
SFV-IL-12, Semliki Forest virus encoding interleukin-12.
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H2-Kb were significantly increased at the peak of the response 
in mice that had been treated with both agents in combination 
(Figure 6c). In good correlation with these results, a significant 
increment in OVA-specific CD8+ T cells was also observed in 
the spleen of mice treated with the combination (Figure 6d).
combination therapy enhanced cd8+ t-cell effector 
responses
Since both IL-12 and CD137 stimulation can lead to T and NK 
cell activation, the combination of both agents could result in 
enhanced IFNγ expression. To check this point, mice were bled 
one day after treatment and serum IFNγ concentrations were 
determined by enzyme-linked immunosorbent assay. IFNγ 
was only detected in SFV-IL-12-treated mice, showing further 
enhanced concentrations in mice treated also with anti-CD137 
mAb (Figure 7a). An enzyme-linked immunospot (ELISPOT) 
assay was also performed at day 7 after treatment by incubat-
ing splenocytes in the presence of major histocompatibility 
complex-I restricted peptides from OVA and TRP-2 proteins. 
For both peptides, mice treated with the combination therapy 
showed the highest number of IFNγ-producing spots, especially 
in the case of the OVA antigenic determinant (Figure 7b).
In-vivo cytotoxicity assays were performed at the same time-point 
revealing that mice receiving an intratumoral injection of SFV-IL-12 
and anti-CD137 mAb intraperitoneally exhibited higher specific lysis 
when challenged with SIINFEKL-loaded splenocytes (Figure 7c, left 
graph). However, we did not observe an increase in specific killing 
when cells were loaded with TRP-2 peptide (Figure 7c, central and 
right graphs). The reasons for the discrepancy between in vivo killing 
and ELISPOT assays remain unknown, but lower TCR avidity in the 
CTLs recognizing an endogenous antigen such as TRP-2, as opposed 























































































SFV-IL-12 + rat IgG
SFV-IL-12 + α-CD137 (bilateral)
Naive
SFV-IL-12 + α-CD137




































0 100 200 300 400
Time (days)
0 20 40 60 80
Time (days)SFV-IL-12(107 vp) SFV-IL-12(107 vp) + α-CD137
a
b c
Figure 3 evaluation of the generation of a protective immune memory response after sFV-Il-12 + anti-cd137 treatment and efficacy in the 
B16.F10 model. (a) Survivor mice from experiments shown in Figures 1a and 2 were rechallenged in a first step with 5 × 105 B16-OVA cells at day 
112 and in a second step with 5 × 105 B16.F10 cells at day 203. When indicated, a group of naive animals were inoculated with the same tumor 
cells to control each rechallenge experiment. Mice survival was monitored and analyzed by sequential Kaplan–Meier plots. The different groups were 
compared with the log-rank test. (b) C57BL/6 female mice were inoculated in the flank with 5 × 105 B16.F10 cells on day 0 and then received an 
intratumoral injection of saline or 107 viral particles (vp) of SFV-IL-12 on day 7. On days 7, 10, and 14 mice received intraperitoneally 100 µg of anti-
CD137 mAb as indicated in the figure. (c) Kaplan–Meier plot of mouse survival. The SFV-IL-12 + anti-CD137-treated group was compared with the 
rest of the groups with the log-rank test. n.s., not significant; *P < 0.05; **P < 0.01. α, anti-; SFV-IL-12, Semliki Forest virus encoding interleukin-12.
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the enhanced therapeutic effect of sFV-Il-12 in 
combination with anti-cd137 mAb is mediated 
by upregulation of cd137 mAb
To understand the mechanisms underlying the synergistic effects 
exhibited by the combination of SFV-IL-12 and CD137 stimula-
tion, we checked the expression levels of CD137 on CD8+ T cells 
in different experimental groups. An SFV vector encoding a LacZ 
irrelevant gene was also included as control to rule out the possible 
effects induced by SFV infection. Interestingly, SFV-IL-12 admin-
istration induced a significant upregulation of CD137 on the sur-
face of tumor infiltrating CD8+ T cells 48 hours after intratumoral 
injection (Figure 8a,b). In contrast, CD137 was only significantly 
upregulated on CD8+ T-cells from tumor-draining lymph nodes 
when both SFV-IL-12 and anti-CD137 mAb were given simulta-
neously (Figure 8c). These results suggest that intratumoral IL-12 
expression could increase the availability of target molecules for 
CD137-agonistic mAbs on CD8+ T cells both in tumor and drain-
ing lymph node environments. More abundant CD137 expression 
would be at least one of the cooperative mechanisms that explain 
why combined treatments attain synergy.
combined therapy reduces humoral immune 
responses against the vector
The presence of SFV-neutralizing antibodies was analyzed at day 
21 after treatment in mice that received SFV-IL-12 in combi-
nation with anti-CD137 mAb, or with a nonrelevant rat IgG as 
control. Interestingly, those animals treated with the combined 
therapy developed SFV neutralizing antibodies at titers that 
were >14-fold lower than those present in animals treated only 
with SFV-IL-12 (Figure 8d). This finding, which is in line with 
previous reports on inhibition of humoral immunity by CD137 
mAb,32,33 represents an additional advantage of the combined 
therapy because lower SFV neutralizing antibody titers would 
allow higher infectivity if several doses of the vector are to be 
used repeatedly.
dIscussIon
Combinatorial treatments are perceived as a major pathway for 
progress in cancer immunotherapy.34 Synergistic effects, rather 
than additive effects are searched for, taking into account the 












































































































































































Figure 4 cd8+ t cell requirement for sFV-Il-12 + anti-cd137 treatment efficacy. (a) C57BL/6 female mice were inoculated in the flank with 5 × 105 
B16-OVA cells on day 0 and then received intratumorally saline (first panel) or 108 viral particles (vp) of SFV-IL-12 (rest of the panels) on day 7. On days 7, 
10, and 14 mice treated with saline received intraperitoneally 100 µg of rat immunoglobulin G (IgG) and mice treated with SFV-IL-12 received a course of 
anti-CD137 mAb as in Figure 1. Depletions of CD4+, CD8β
+, and NK1.1+ cells were performed by intraperitoneal injection of 100 µg of specific antibod-
ies administered at days 6, 10, 15, 21, and 28 for αCD4+ and αCD8+ and at days 6, 8, 10, 12, 15, 21, and 28 for αNK1.1+. Each curve represents the 
evolution of the mean tumor diameter for each individual mouse. The numbers in the right lower corner of each graph indicate the number of tumor-
free mice on day 70 relative to the total number of animals in each group, and the percentage of sustained complete tumor regressions, respectively. 
(b) Kaplan–Meier plot of mouse survival. The different groups were compared with the log-rank test. **P < 0.01;***P < 0.001. The graphs correspond to 
pooled data from two independent experiments with similar results. α, anti-; SFV-IL-12, Semliki Forest virus encoding interleukin-12.
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have explored and documented the efficacy of combined intratu-
moral injections of a SFV-based vector encoding IL-12 and sys-
temic treatment with an agonist anti-CD137 mAb. Such a strategy 
is certainly feasible because two human antibodies directed to 
CD137 are currently undergoing clinical trials, and the produc-
tion of clinical-grade alphaviruses has been reported35 and is in 
progress in our institution.
Previous work had defined that IL-12-based gene transfer 
with adenoviral vectors and stimulation of the CD137 pathway 
can be combined in mouse models.27 In our studies we set out to 
exploit several of the unique features of SFV encoding IL-12 to 
turn a tumor lesion into an immunogenic vaccine. In this regard 
SFV-IL-12: (i) releases locally abundant IL-12, (ii) kills infected 
malignant cells in a stressful fashion,36 (iii) fills the cells with rep-
licating viral RNA which turns on the innate immune response.4 
Tumor antigens under these conditions should dramatically 
increase their immunogenicity. This probably explains why SFV-
IL-12 achieves potent therapeutic results in immunotherapy of 
transplanted tumors and partial efficacy in spontaneous hepato-
cellular carcinomas in woodchucks.4,10,16
Immunostimulatory mAbs provide versatile tools to release 
the brakes or step on the gas pedals of immune system cells.25 
There is panoply of examples in which these agents synergize with 
cancer vaccines.37 CD137 costimulation is one of the most potent 
examples in this regard.37 In this study, we changed this paradigm 
to locally transform at least part of the tumor lesion into a potent 
immunogen, whose effect would be multiplied by providing 
CD137 costimulation to primed T lymphocytes. We have previ-
ously tried to pursue a similar goal injecting tumor lesions with 
type I IFN.38 However, it is clear that intratumoral treatment with 
SFV-IL-12 is endowed with manifold more immunogenic char-
acteristics than a local release of a single recombinant cytokine. 
Efficacy of CD137 agonists in monotherapy relies on dendritic 
cell-mediated tumor antigen crosspriming39 and thereby enhanc-
ing immunogenic crosspresentation of tumor antigens upon SFV 
infection should attain more efficacious therapeutic outcomes. It 
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Figure 5 sFV-Il-12 + anti-cd137 therapy augments the cd8/treg ratio and the quality of cd8+ t cells. C57BL/6 female mice were flank-
inoculated with 5 × 105 B16-OVA cells on day 0 and then received intratumorally saline or 108 viral particles (vp) of SFV-IL-12 on day 7. On days 7 and 
10 mice received intraperitoneally 100 µg of rat immunoglobulin G (IgG) or anti-CD137 mAb. On day 11 mice were sacrificed and tumors were har-
vested, processed, and analyzed by flow cytometry. (a) Graphs show the number of CD8+ T cells (left), Tregs (middle), and the ratio between CD8+ 
T and Treg lymphocytes (right). The results are represented as the mean ± standard error of mean (SEM). (b) Representative dot plots of CD25 and 
FoxP3 expression on CD4+ T cells. Numbers indicate the percentages of cells in each quadrant analyzed by fluorescence-activated cell sorting (FACS). 
Tregs are identified in the upper-right quadrants as CD4+CD25+Foxp3+ cells. (c) Plots showing FACS-assessed size and complexity of intratumoral 
CD8+ T cells. The values on the right upper corner of each panel represent the mean ± SD for FSC or SSC. *P < 0.05; **P < 0.01; α, anti-; SFV-IL-12, 
Semliki Forest virus encoding interleukin-12.
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is likely that tumor cell death provides antigen material ready for 
crosspresentation by surrounding DCs. In this regard, we have 
observed that both treatment with antibody and the combined 
treatment enhanced the level of dendritic cell activation in the 
tumor tissue (data not shown).
In this study, efficacy was defined using established B16-OVA 
and B16.F10 melanomas as well as TC-1 lung carcinomas. In both 
cases, intrinsic immunogenicity is low and defined tumor antigens 
are available to monitor the immune response. Doses of SFV-IL-12 
were titrated first to allow us to observe the synergy. Reducing vec-
tor doses offers also a safety advantage because of the toxicity profile 
of IL-12.9 It is of interest that the synergistic combination achieved 
efficacy in all tested models, including established B16.F10 melano-
mas devoid of any model antigen. Efficacy on this immunotherapy-
refractory tumor is a promising feature for clinical translation.
The most prominent observation is that combined treat-
ment with SFV-IL-12 and CD137 agonist mAb elicits a very 
robust CTL-mediated immune response able to completely 
eliminate most treated tumors and retard growth in concomi-
tant malignant lesions. In contrast to studies from the group of 
Chen and colleagues with IL-12-encoding adenovirus, in our 
case NK cells were dispensable for antitumor activity.27 NK 
were not needed in previous reports of efficacious treatments 
with SFV-IL-12 in monotherapy,10 while the effects of CD137 
agonist antibodies are NK-dependent in various models.20 
Upon CD8β depletion some retardation of the tumors was still 
observed that could be related to the described antiangiogenic 
effects of IL-12 encoded by SFV vectors.29 Surprisingly, tumor 
infiltrates showed reductions in absolute numbers of NK/NKT 
cells, in spite of the well known IL-12 effects on these lym-
phocyte subsets. Although we do not have yet a mechanistic 
explanation it is of note that recent information suggests that 
NK cells can be harmful for the elicitation of systemic CD8 
memory.40
In the case of B16-OVA, the CTL response against OVA is 
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Figure 6 combined treatment increases cd8+ t cell and tumor-specific cd8+ t cell numbers. (a–c) C57BL/6 female mice were inoculated in 
the flank with 5 × 105 B16-OVA cells on day 0 and then received intratumorally saline or 108 viral particles (vp) of SFV-IL-12 on day 7. On days 7, 10, 
and 14 mice received intraperitoneally 100 µg of rat immunoglobulin G (IgG) or anti-CD137 mAb. Mice were bled at days 7, 11, 15, 19, 22, 27, and 
35 and percentages of CD8+ T cells (a,b) or the number of CD8+ T cells per 106 peripheral blood mononuclear cells which were OVA- (c, left panel) 
or tyrosine-related protein-2 (TRP-2)-specific (c, right panel) were determined by flow cytometry. (d) C57BL/6 female mice were inoculated in the 
flank with 5 × 105 B16-OVA cells on day 0 and then received intratumorally saline or 108 vp of SFV-IL-12 on day 7. On days 7 and 10 mice received 
intraperitoneally 100 µg of rat IgG or anti-CD137 mAb. On day 11 mice were sacrificed and spleens were harvested, processed, and analysed by flow 
cytometry. The graph shows the number of OVA-specific CD8+ T cells in the spleens of treated mice. *P < 0.05; **P < 0.01; ***P < 0.001. α, anti-; 
SFV-IL-12, Semliki Forest virus encoding interleukin-12.
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while the response to the melanosomal protein TRP-2 seems 
weaker. However, we have observed vitiligo surrounding the areas 
where the tumor had been grafted in about half of the mice cured 
from B16-OVA (Supplementary Figure S7).
The mechanisms of synergy between CD137 stimulation and 
SFV-IL-12 intratumoral injection can be multiple. The simplest 
synergistic mechanism would be that SFV-IL-12 injection would 
prime tumor-specific CTL to express CD137 on the surface. Once 
the target for the immunostimulatory mAb becomes available 
and is ligated by mAb, such CTL are protected from apopto-
sis and enhanced in their performance. Other proinflammatory 
mediators elicited by SFV at the tumor microenvironment beyond 
IL-12 are likely to be involved, including type I IFN and chemok-
ines. Such factors acting in concert are known to enhance CTL 
responses while attracting effector lymphocytes toward infected 
tissue. Indeed other ongoing studies from our group show the 
absolute need of the type I IFN system for the antitumor effects 
of SFV-IL-12 (S. Hervas-Stubbs et al., manuscript in preparation). 
In agreement with these observations, we also showed that SFV 
replication in tumors was a requirement to achieve a good syn-
ergy between IL-12 and anti-CD137 antibodies (Supplementary 
Figure S2b).
Another effect of anti-CD137 agonist antibodies is the sup-
pression of ongoing humoral responses acting on T helper 
cells32 and the network of follicular dendritic cells.33 We have 
documented that the response against SFV particles is mark-
edly downsized by anti-CD137 mAb, reaching levels that would 
allow an efficient readministration of the SFV vector.41 This has 
implications for treatment repetitions that might extend the 
therapeutic effects.
Overall, we have defined a clinically feasible and potent thera-
peutic combination encompassing intratumoral treatments with 
SFV-IL-12 and systemic costimulation with anti-CD137 mAb. The 
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Figure 7 enhancement of immune responses with sFV-Il-12 + anti-cd137 combined therapy. C57BL/6 female mice were subcutaneously 
inoculated with 5 × 105 B16-OVA cells on day 0 and then received intratumorally saline or 108 viral particles (vp) of SFV-IL-12 on day 7. On days 7 
and 10 mice received intraperitoneally 100 µg of rat immunoglobulin G (IgG) or anti-CD137. (a) At day 1 after treatment onset, mice were bled and 
sera samples were analyzed by enzyme-linked immunosorbent assay (ELISA) to determine interferon γ (IFNγ) concentrations. The results are repre-
sented as the mean ± SEM (n = 4 per group). ND, not detected. (b) On day 14, mice were sacrificed and spleens were processed to carry out an IFNγ 
enzyme-linked immunospot (ELISPOT) assay using OVA or tyrosine-related protein (TRP)-specific peptides for stimulation. The data are represented 
as number of IFNγ-producing spots per 106 splenocytes. (c) In-vivo killing assay. On day 13, tumor peptide-pulsed splenocytes from naive CD45.1 
mice were injected to treated mice and 20 hours later mice were sacrificed and spleens collected. The percentage of specific cell lysis was quantified 
by flow cytometry. The set histograms in the right show representative cases of this experiment. n.s., not significant; *P < 0.05; **P < 0.01. α, anti-; 
SFV-IL-12, Semliki Forest virus encoding interleukin-12.
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antigen presentation that primes CTL, which upon becoming 
activated receive the stimuli of IL-12 and anti-CD137 mAb in a 
context that resembles many of the danger signals featuring viral 
infections that so potently elicit CTL responses.
MAterIAls And Methods
Cell lines and animals. The BHK-21 cell line (ATCC CCL-10) was cultured 
as described previously.10 The murine melanoma cell line B16.F10 and the 
OVA-expressing variant B16-OVA (H-2b) and the TC-1 cell line, a lung 
epithelial cell line transformed by the HPV-16 E6 and E7 oncogenes,30 were 
tested to be mycoplasma-free and verified for identity by Johns Hopkins 
Genetic Resources Core Facility. Five-week-old female C57BL/6 mice were 
purchased from Harlan Laboratories (Barcelona, Spain). Animal studies 
were approved by the institutional ethical committee for animal experi-
mentation under Spanish regulations.
Vector production. Plasmids pSFV-enhLacZ, pSFV-Luc, and pSFV-
enhIL-12 have been described previously.10,42 RNA synthesis from SFV 
plasmids, transfection into BHK-21 cells by electroporation, and packag-
ing of recombinant RNA into SFV vp were performed as described previ-
ously.36 Briefly, BHK-21 cells were co-electroporated with the recombinant 
RNA, together with two helper RNAs (i.e., SFV-helper-C-S219A and 
SFV-helper-S2 RNAs), which provided in trans the capsid and the spike 
proteins, respectively.43 SFV vp were harvested and purified by ultracen-
trifugation as described previously.44 Indirect immunofluorescence was 
applied to SFV-infected BHK-21 cells to determine the titer of SFV-Luc, 
SFV-enhLacZ, and SFV-enhIL-12 (designated in this manuscript as SFV-
LacZ and SFV-IL-12, respectively) recombinant virus stocks as described 
previously.45 The cytopathic effect induced by SFV-IL-12 on tumor cell 
lines was determined by infecting cell monolayers of B16-OVA and TC-1 
with a multiplicity of infection of 1,000 (Supplementary Figure S2a).
In-vivo tumor experiments. Mice were injected with B16-OVA, B16.F10, 
or TC-1 cells (5 × 105 cells per animal) subcutaneously in the right flank 
or in both flanks as detailed in each experiment. Treatments were given 
from 7 to 8 days (B16) and 18 to 21 days (TC-1) after tumor inoculation 



















































































Figure 8 sFV-Il-12 + anti-cd137 combined therapy up-regulates cd137 on cd8+ t cells and reduces anti-sFV humoral immune responses. 
(a–c) B16-OVA tumor-bearing mice were treated intratumorally with saline or 108 viral particles (vp) of SFV-LacZ or SFV-IL-12 on day 7. The same day 
mice received intraperitoneally 100 µg of rat immunoglobulin G (IgG) or anti-CD137 mAb. Two days later, mice were sacrificed and tumor nodules 
and draining lymph nodes (DLNs) were processed and analyzed by flow cytometry. (a) Plots showing CD137 expression level on CD8+ T cells from 
tumor nodules. (b,c) Graphs showing the percentage of CD8+ T cells that upregulate CD137 expression on their surface in tumor nodules or DLNs, 
respectively. (d) B16-OVA tumor-bearing mice treated with SFV-IL-12 + rat IgG, or anti-CD137 mAb, as described in Figure 1, were bled at day 21 
and sera samples were analyzed to determine anti-SFV neutralizing antibody titers. The results are represented as mean ± SEM. *P < 0.05; **P < 0.01. 
α, anti-; SFV-IL-12, Semliki Forest virus encoding interleukin-12.
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diameter. SFV-IL-12 resuspended in 30 μl of phosphate-buffered saline 
was injected intratumorally with 28G needles. Anti-CD137 mAb was 
produced from the 2A hybridoma (kindly provided by Dr Lieping Chen, 
Yale University, New Haven, CT). The mAb was purified from culture 
supernatant, dialyzed and quality controlled including determinations of 
lipopolysaccharide concentration (Antibody BCN, Barcelona, Spain, as a 
contractor). Control IgG from rat serum was obtained from Sigma-Aldrich 
(Dorset, UK). Tumor growth was monitored every 3–4 days by measuring 
two perpendicular tumor diameters, and considering the average diameter 
as an indicator of tumor size.
Depletion of immune cells. Depletions of CD4+, CD8+, or NK1.1+ were 
performed by intraperitoneal injections of 100 µg of specific antibodies 
against CD4 (GK 1.5), CD8β (H3S-17-2), and NK1.1 (PK136). Anti-CD4 
and anti-CD8β antibodies were injected at days 6, 10, 15, 21, and 28 after 
tumor inoculation. Anti-NK1.1 antibody was injected at days 6, 8, 10, 12, 
15, 21, and 28 after tumor cell inoculation. Depletions were monitored by 
FACS analysis and only mice with a depletion efficacy higher than 99% for 
each specific cell type were used.
In-vivo killing assay. Splenocytes from naive C57BL/6 mice congeneic for 
the CD45.1 allele were divided into three different samples. Two of these 
samples were pulsed with 10 μg/ml of the OVA257–264 peptide (SIINFEKL; 
NeoMPS, Strasbourg, France) or the TRP-2180–188 peptide (SVYDFFVWL) 
for 30 minutes at 37 °C in 5% CO2 and washed extensively. The third part 
remained without any peptide as an additional control. OVA-pulsed, TRP-
2-pulsed, and nonpulsed splenocytes were then labeled with 1 μmol/l 
(CFSEhi), 100 nmol/l (CFSEmed), or 10 nmol/l (CFSElow) of CFSE (Sigma-
Aldrich), respectively. The three samples were mixed at the same ratio and 
injected intravenously (5 × 106 cells of each population) into B16-OVA-
bearing or naive mice. Twenty hours later, spleens were harvested and 
transferred target cells were gated using an anti-CD45.1 PE-conjugated 
antibody. Specific cytotoxicity was analyzed by flow cytometry and calcu-
lated as follows: 100 − [100 × (% CFSEhi or CFSEmed tumor-bearing mice/% 
CFSElow tumor-bearing mice)/(%CFSEhi or CFSEmed naive mice/% CFSElow 
naive mice)].
Serum determination of IFNγ by enzyme-linked immunosorbent assay 
and IFNγ-ELISPOT assays. IFNγ concentrations were determined in sera 
using a mouse IFNγ-specific enzyme-linked immunosorbent assay kit 
(BD Bioscience, Franklin Lakes, NJ). ELISPOT assays for the detection 
of tumor-specific interferon-γ-producing spleen cells were performed as 
described.46 4 × 105 spleen mononuclear cells from the different groups 
of mice were incubated for 24 hours with or without the specific peptide 
(OVA257–264 or TRP-2180–188). Spots were quantified using the automated 
CTL-ImmunoSpot S5 Micro Analyzer (CTL-Europe, Bonn, Germany) and 
results were expressed as number of spots/106 spleen mononuclear cells.
Isolation of mononuclear cells from lymph node and tumors and flow 
cytometry. To obtain unicellular cell suspensions, tumor-draining lymph 
nodes from pooled inguinal, brachial, and axilar lymph nodes from tumor-
bearing mice, subcutaneous tumor nodules, and spleens were surgically har-
vested. These organs were incubated in Collagenase-D and DNase-I (Roche, 
Basel, Switzerland) for 15 minutes at 37 °C. Dissociated cells were passed 
through a 70-μm nylon mesh filter (BD Falcon, BD Bioscience, San Jose, 
CA). Single-cell suspensions were pretreated with FcR-Block (anti-CD16/32 
clone 2.4G2; BD Biosciences-Pharmigen, San Jose, CA). Afterwards, cells 
were stained with specific antibodies for CD8, CD4, CD3, CD137, NK1.1, 
CD11b (M1/70), Ly6G (1A8), Ly6C (AL21), CD25, and FoxP3, as well as 
using Mouse regulatory T cell staining kit purchased from e-bioscience 
(catalog number 88–8,111). To identify tumor-specific CD8 T lymphocytes, 
cells were stained with the iTAg major histocompatibility complex class I 
tetramer loaded with the SIINFEKL synthetic peptide and the TRP-2-
specific pentamer conjugated with PE. For tetramer kinetics, blood samples 
were extracted at indicated time points by tail bleeding. Cells were analyzed 
with a FACSCalibur or FACSCanto (BD, San Agustin de Guadalix, Spain) 
and FlowJo software.
Evaluation of anti-SFV neutralizing antibodies in SFV-treated mice. The 
presence of SFV neutralizing antibodies in serum of SFV-treated animals 
was analyzed by performing an in vitro infection assay of BHK cells with 
SFV-Luc in the presence of different amounts of sera from the SFV-treated 
animals.10
Statistical analyses. All error terms are expressed as the SEM. Monolix 
software (http://www.monolix.org/) was used for analysis of tumor growth 
by non-linear mixed effect models in bilateral experiments. Prism software 
(GraphPad Software, San Diego, CA) was employed for the rest of statisti-
cal analysis. Survival of tumor bearing animals was represented by Kaplan–
Meier plots and analyzed by log-rank tests. Data were analyzed first by the 
Kolmogorov–Smirnov Normality test. Mann–Whitney U-test was used to 
compare two experimental groups. One-way ANOVA or Kruskal–Wallis 
tests followed by Bonferroni or Dunn’s Multiple comparison tests were 
used to compare four experimental group experiments, depending on 
whether the data were or were not from a normally distributed sample, 
respectively. P values <0.05 were considered to be statistically significant.
suPPleMentArY MAterIAl
Figure S1. Evaluation of antitumor efficacy of SFV-IL-12 in B16-OVA 
tumors.
Figure S2. Analysis of cytopathic effect of SFV-IL-12 in tumor cells and 
role of SFV replication on antitumoral efficacy in combined treatment.
Figure S3. Evaluation of antitumor efficacy of SFV-IL-12 in TC-1 
tumors.
Figure S4. Treatment efficacy of SFV-IL-12 + anti-CD137 combina-
tion on bilateral tumors is not mediated by dissemination of the viral 
vector but immune system mediated.
Figure S5. Tumor infiltrating leukocytes.
Figure S6. Depletion of myeloid cells does not affect antitumor ef-
ficacy of SFV-IL-12 + anti-CD137 mAb treatment.
Figure S7. Vitiligo occurrence in cured mice.
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